Altimmune Inc logo

Altimmune Inc(ALT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.41
11/19/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ALT

11/19/2026: ALT (1-star) is currently NOT-A-BUY. Pass it for now.

Altimmune Inc is a clinical-stage biopharmaceutical company developing peptide-based therapeutics focused on obesity and metabolic liver diseases. Its primary asset, pemvidutide, demonstrates promising potential in reducing body weight and liver fat. The company's main growth opportunity lies in capturing market share within the rapidly expanding metabolic disease therapeutic space. However, Altimmune faces substantial execution risks, ongoing operating losses, and fierce competition from well-capitalized pharmaceutical giants. This stock suits high-risk growth investors willing to monitor clinical trial readouts and capital-raising updates closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high-growth potential tied to clinical milestones, but lacks current commercial revenue.
Momentum investorStrong fit while signal remains positiveStock price movements can be sharp and rapid around clinical trial data releases.
Value investorWeak fitLacks earnings, book value anchors, or cash flows typical of value investments.
Dividend investorWeak fitThe company pays no dividends and retains all capital for clinical trials.
Low-risk investorWeak fitHigh binary clinical and regulatory risks create substantial stock volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience severe price swings around trial readouts.
Valuation riskHighValuations are speculative and depend entirely on future drug approval outcomes.
Competition riskHighWell-funded competitors dominate the obesity therapeutic market with approved blockbuster drugs.
Business qualityMediumThe company possesses promising scientific assets but lacks a diversified commercial portfolio.
Dividend incomeLow / noneNo dividend is paid or expected in the near term.
Execution riskHighSuccess relies entirely on successfully executing clinical trials and securing regulatory clearances.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 270.48M USD
Price to earnings Ratio -
1Y Target Price 16.33
Price to earnings Ratio -
1Y Target Price 16.33
Volume (30-day avg) 3.9M shares
Beta 0.15
52 Weeks Range 1.38 - 6.44
Updated Date 11/19/2026
52 Weeks Range 1.38 - 6.44
Updated Date 11/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.71

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
61.0%
Active BUY / eligible
64 / 105
30-Day BUY Count Change
+16
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
44.7%
Active BUY / eligible
17 / 38
30-Day BUY Count Change
+9

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -18.17%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/19/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ALT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ALT has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+7.3%) and strong revenue growth (+105.0%) are partially offset by weak cash generation (FCF margin -164746.3%), weak profitability (net margin -214861.0%), very low insider ownership of 0.47%.

Financial Health Rating

★★★★★
ALT's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 94.0%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is ALT's strongest growth driver at +105.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+15.4%, solid) is also solid, while earnings growth (+7.3%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 73.9% and approximately 89.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.47%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 10.48%
Deep Track Capital, LP 9.90%
State Street Corp 6.22%
TCG Crossover Management, LLC 5.14%
Vanguard Capital Management, LLC 4.20%

Unit Economics (Per $1K Revenue)

★★★★★
ALT generates approximately $1,000 of gross profit, $-2,304,610 of operating income, and $-1,647,463 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.77%

Quantitative Style Profile

★★★★★
ALT has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical Research and DevelopmentClinical-stage development of therapeutic peptide candidates like pemvidutide for obesity and liver diseases.The company currently does not generate product sales and operates as a pre-revenue clinical developer.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 8.18
Enterprise Value 41.62M
Price to Sales(TTM) 10440.47
Enterprise Value 41.62M
Price to Sales(TTM) 10440.47
Enterprise Value to Revenue 1600.86
Enterprise Value to EBITDA 11.93
Shares Outstanding 194.59M
Shares Floating 174.31M
Shares Outstanding 194.59M
Shares Floating 174.31M
Percent Insiders 0.47
Percent Institutions 73.92

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.